Erudio Healtherudio.com
Drug
Linvoseltamab trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying linvoseltamab: LINKER-AL2. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LINKER-AL2 NCT06292780 · Regeneron Pharmaceuticals | relapsed or refractory systemic light chain amyloidosis | Phase 1/Phase 2 | 149 | 26 | Focused | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LINKER-MM1 NCT03761108 · Regeneron Pharmaceuticals DeepView → | relapsed or refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| LINKER-MM4 NCT05828511 · Regeneron Pharmaceuticals DeepView → | newly diagnosed multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| IMMUNOPLANT NCT06376526 · Dickran Kazandjian, MD DeepView → | newly diagnosed multiple myeloma | Phase 2 | Deep | View | |||
| LINKER-MM3 NCT05730036 · Regeneron Pharmaceuticals StandardView → | relapsed/refractory multiple myeloma | Phase 3 | Standard | View | |||